Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
The sustained coronavirus pandemic is leading to especially large windfalls for labs and companies that make the materials used for testing.
The big picture: Detecting widespread infection and helping set up clinical trials isn't free, and the botched federal response will keep demand for these supplies high for a long time.
By the numbers: Investors in companies directly involved with coronavirus testing are starting to reap their largest rewards six months into the pandemic.
- Thermo Fisher, which makes test kits, reagents and materials used in vaccine and coronavirus drug trials, said third-quarter profit more than doubled compared to last year, reaching $1.9 billion. Revenue soared 36% to $8.5 billion. More than 20% of its revenue was tied to COVID-19 tests, equipment and services.
- LabCorp said its third-quarter earnings more than tripled as COVID-19 test demand continued to surge and other routine lab tests started to come back.
- Quest Diagnostics also said its profit doubled.
What they're saying: "We're on track to achieve a truly spectacular year," Thermo Fisher CEO Marc Casper told Wall Street this week after the company raised its full-year revenue and profit projections by 14% and 35%, respectively. "It's exciting to be able to set a new bar on performance, right?"
Between the lines: Enhanced federal payments for COVID-19 tests, as well as a one-year reprieve from Medicare cuts, will buoy labs.
- Medicare has guaranteed $100 payments for COVID-19 tests if labs can turn around test results within two days, but Medicare will still pay $75 if that timeline isn't met — higher than the $51 Medicare was initially paying.